Rydapt (midostaurin)

Save 60% on brand name Rydapt from Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Manufacturer for Europe Novartis Pharma GmbH Roonstrasse 25 90429 Nuremberg Germany

Information about Rydapt (Midostaurin)

Rydapt (midostaurin) is an oral kinase inhibitor used in the treatment of certain types of cancers. It targets specific proteins, called kinases, that are involved in the growth and survival of cancer cells. Midostaurin is used primarily for the treatment of acute myeloid leukemia (AML) and systemic mastocytosis. By inhibiting these kinases, Rydapt helps to stop or slow the growth of cancer cells. It is commonly used alongside other treatments. 

Product Highlights

• Rydapt is indicated for the treatment of adult patients with FLT3 mutation-positive AML, a form of leukemia where the FLT3 gene is mutated, leading to uncontrolled cell growth.
• Rydapt is used for the treatment of adult patients with systemic mastocytosis, a condition where excessive mast cells accumulate in various tissues and organs, causing symptoms like swelling, rash, and severe allergic reactions.

Key Ingredient

• Midostaurin

Key Benefits

• Rydapt is particularly effective in treating AML with FLT3 mutations, a subtype of leukemia that has a poor prognosis without targeted treatment.
• When used in combination with chemotherapy, Rydapt helps improve survival rates and progression-free survival in patients with FLT3-mutated AML.
• In patients with systemic mastocytosis, Rydapt helps reduce symptoms related to excessive mast cell proliferation and accumulation, such as skin rashes and allergic reactions.
• Rydapt is administered in pill form, offering the convenience of an oral medication as opposed to intravenous therapies.
• By targeting multiple pathways, including those related to FLT3, KIT, and PDGFR, Rydapt has a broad therapeutic effect on various cancer-related processes.

Direction of Use

• The usual recommended dose for FLT3-mutated AML is 50 mg twice daily (morning and evening), taken with food.
• The usual recommended dose for systemic mastocytosis is 100 mg twice daily.
• Rydapt should be taken with food to increase absorption. The capsules should be taken whole and not crushed or chewed. 
• Patients should be closely monitored for side effects, especially during the first few weeks of treatment. Blood tests to monitor liver function, blood counts, and other parameters may be required.

Safety Concerns

• As a chemotherapy agent, Rydapt can weaken the immune system, increasing the risk of infections. Patients should be carefully observed for any signs of infection. 
• Liver function should be monitored regularly, as midostaurin can cause liver problems such as elevated liver enzymes or jaundice.
• Rydapt may increase the risk of bleeding or bruising, especially in combination with other anticoagulants or blood thinners.
• Midostaurin can prolong the QT interval (a measure of heart rhythm), which could lead to serious heart arrhythmias in some patients. It is important to monitor heart health during treatment.
• Some patients may experience nausea, vomiting, or diarrhea. These symptoms should be managed to prevent dehydration and discomfort.

Avoid Rydapt (Midostaurin) If

• Do not use Rydapt if you are allergic to midostaurin or any of its ingredients. 
• Patients with severe liver disease or elevated liver enzymes should avoid Rydapt or use it with caution and under strict medical supervision.
• Rydapt is not recommended during pregnancy due to potential harm to the fetus. It should also be avoided during breastfeeding, as it may pass into breast milk and harm the infant.
• If you have a history of QT prolongation, heart arrhythmias, or other serious heart conditions, you should not take Rydapt unless specifically directed by your healthcare provider.
• If you have an active infection, Rydapt should be avoided until the infection is controlled.